Related Experiment Video
Updated: May 17, 2026
09:52
Genetic Manipulation in Δku80 Strains for Functional Genomic Analysis of Toxoplasma gondii
Published on: July 12, 2013
Targeting UDP-galactopyranose mutases from eukaryotic human pathogens
Karina Kizjakina1, John J Tanner, Pablo Sobrado
1Department of Biochemistry, Virginia Tech, Blacksburg, VA 24061, USA.
Current Pharmaceutical Design
|November 3, 2012
Summary
UDP-Galactopyranose mutase (UGM) is crucial for pathogen virulence. This review compares eukaryotic and prokaryotic UGMs, highlighting differences and conserved features for potential drug development.
Area of Science:
- Biochemistry
- Enzymology
- Drug Discovery
Background:
- UDP-Galactopyranose mutase (UGM) catalyzes a key reaction producing UDP-galactofuranose (UDP-Galf), a precursor for essential cell wall and cell surface components in pathogens.
- UGM's vital role in the virulence of fungi, parasites, and bacteria, coupled with its absence in humans, makes it a promising drug target.
Purpose of the Study:
- To review recent findings on eukaryotic UGMs.
- To compare eukaryotic UGMs with their prokaryotic counterparts, focusing on structural and mechanistic differences.
Main Methods:
- Comparative analysis of structural and mechanistic features of UGMs from prokaryotic and eukaryotic organisms.
- Review of recent research on eukaryotic UGM enzymes.
Main Results:
- Eukaryotic and prokaryotic UGMs exhibit distinct structural and mechanistic properties, including differences in oligomeric state, substrate binding, active site flexibility, and redox partner interactions.
- Despite differences, the flavin cofactor's conserved role in catalysis is a unifying feature across the UGM enzyme family.
Conclusions:
- UGMs from eukaryotes and prokaryotes possess unique characteristics, necessitating tailored approaches for drug development.
- Understanding these differences is critical for designing effective therapeutics targeting UGM in human pathogens.
Related Concept Videos
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...